Press Releases

- Analysis includes data from ACT DMD on deflazacort and prednisone/prednisolone -

SOUTH PLAINFIELD, N.J. , May 19, 2017 /PRNewswire/ --  PTC Therapeutics, Inc.  (NASDAQ: PTCT) today announced that on May 17, 2017 it approved non-statutory stock options to purchase 46,500 shares of its common stock to ten new employees. The awards were made pursuant to the NASDAQ inducement grant

- Translarna™ first quarter net sales of $26.4M representing 40% year-over-year growth -
- Full-year 2017 Translarna net sales guidance increased to $115 to $130M -
- EMFLAZATM for the treatment of Duchenne muscular dystrophy planned to launch in the coming weeks -

SOUTH PLAINFIELD, N.J. , April 26, 2017 /PRNewswire/ -- PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that on April 21, 2017 it approved non-statutory stock options to purchase 266,400 shares of its common stock to 32 new employees. The awards were made pursuant to the NASDAQ inducement

SOUTH PLAINFIELD, N.J. , April 24, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its first quarter financial results and provide an update on the company's business and outlook on Monday, May 8, 2017 at

SOUTH PLAINFIELD, N.J. , April 20, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced it has completed its acquisition of all rights to Emflaza™ (deflazacort) for the treatment of Duchenne muscular dystrophy (DMD) in the U.S. Execution of the asset purchase agreement

SOUTH PLAINFIELD, N.J. , April 10, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that Shane Kovacs , Chief Financial Officer, will be leaving the company in mid-May 2017 to return to the finance sector, joining RBC Capital Markets as Managing Director where he will

- $81.4M in Translarna net sales, a 142% increase vs. 2015 -
- October 24th PDUFA target date for Translarna nmDMD NDA -
- SMA program actively enrolling patients across SUNFISH and FIREFISH trials -
- Translarna 2017 net sales guidance of $105M to $125M -

- Emflaza is the first treatment approved in the U.S. for DMD patients 5 years and older, regardless of genetic mutation
- Aligns with PTC's mission and commitment to the DMD community
- $140 million upfront consideration (comprised of cash and PTC common stock) plus potential contingent payments based on net sales and single milestone payment
- PTC to host investor conference call today, March 16, 2017 at 8:30 am ET

SOUTH PLAINFIELD, N.J. , March 13, 2017 /PRNewswire/ --  PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the Company will host a webcast conference call to report its fourth quarter and year end 2016 financial results and provide an update on the company's business and outlook on